CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
CH Biotech R&D Co., Ltd. (6534) - Net Assets
Latest net assets as of September 2025: NT$2.62 Billion TWD
Based on the latest financial reports, CH Biotech R&D Co., Ltd. (6534) has net assets worth NT$2.62 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.68 Billion) and total liabilities (NT$1.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.62 Billion |
| % of Total Assets | 71.23% |
| Annual Growth Rate | 15.64% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.51 |
CH Biotech R&D Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how CH Biotech R&D Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CH Biotech R&D Co., Ltd. (2020–2024)
The table below shows the annual net assets of CH Biotech R&D Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.65 Billion | +5.02% |
| 2023-12-31 | NT$2.52 Billion | +20.72% |
| 2022-12-31 | NT$2.09 Billion | +21.15% |
| 2021-12-31 | NT$1.72 Billion | +16.44% |
| 2020-12-31 | NT$1.48 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CH Biotech R&D Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 207.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$556.97 Million | 21.05% |
| Common Stock | NT$1.03 Billion | 38.85% |
| Other Components | NT$1.06 Billion | 40.10% |
| Total Equity | NT$2.65 Billion | 100.00% |
CH Biotech R&D Co., Ltd. Competitors by Market Cap
The table below lists competitors of CH Biotech R&D Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Circus SE
XETRA:CA1
|
$93.85 Million |
|
Gamehost Inc
PINK:GHIFF
|
$93.87 Million |
|
TiumBio Co. Ltd
KQ:321550
|
$93.90 Million |
|
Barton Gold Holdings Ltd
AU:BGD
|
$93.91 Million |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
$93.83 Million |
|
Pharmosa Biopharm Inc.
TWO:6875
|
$93.73 Million |
|
Asia Plus Group Holdings PCL
BK:ASP
|
$93.67 Million |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
$93.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CH Biotech R&D Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,520,148,000 to 2,645,875,000, a change of 125,727,000 (5.0%).
- Net income of 476,386,000 contributed positively to equity growth.
- Dividend payments of 369,052,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$476.39 Million | +18.0% |
| Dividends Paid | NT$369.05 Million | -13.95% |
| Other Changes | NT$18.39 Million | +0.7% |
| Total Change | NT$- | 4.99% |
Book Value vs Market Value Analysis
This analysis compares CH Biotech R&D Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.27x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.53x to 3.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$15.15 | NT$83.80 | x |
| 2021-12-31 | NT$17.57 | NT$83.80 | x |
| 2022-12-31 | NT$21.17 | NT$83.80 | x |
| 2023-12-31 | NT$25.73 | NT$83.80 | x |
| 2024-12-31 | NT$25.61 | NT$83.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CH Biotech R&D Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.00%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.12%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.37x
- Recent ROE (18.00%) is above the historical average (16.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 6.77% | 14.26% | 0.24x | 1.95x | NT$-47.83 Million |
| 2021 | 16.92% | 28.62% | 0.34x | 1.76x | NT$119.18 Million |
| 2022 | 22.29% | 32.45% | 0.45x | 1.53x | NT$256.66 Million |
| 2023 | 18.38% | 30.58% | 0.42x | 1.45x | NT$211.28 Million |
| 2024 | 18.00% | 29.12% | 0.45x | 1.37x | NT$211.80 Million |
Industry Comparison
This section compares CH Biotech R&D Co., Ltd.'s net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $16,553,276,750
- Average return on equity (ROE) among peers: 8.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CH Biotech R&D Co., Ltd. (6534) | NT$2.62 Billion | 6.77% | 0.40x | $93.83 Million |
| Sinon Corp (1712) | $7.11 Billion | 10.07% | 1.10x | $442.00 Million |
| Taiwan Fertilizer Co Ltd (1722) | $54.27 Billion | 1.72% | 0.50x | $922.26 Million |
| All Cosmos Bio-Tech Holding Corp (4148) | $2.38 Billion | 8.33% | 0.25x | $32.62 Million |
| Huikwang (6508) | $2.45 Billion | 13.42% | 0.30x | $40.53 Million |